18 results about "Tryptamine" patented technology

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention provides a preparation method of an efficient selective antagonist BQ-788, and relates to the technical field of preparation of antagonists. A solid-liquid combination method is adopted for synthesis, due to the fact that dimethyl dialkanoate on a side chain of tryptophan (DTrp) is difficult, Fmoc-DTrp (CO2Me)-OH is obtained through liquid-phase synthesis, p-methoxybenzyl is selected for protecting carboxyl in the synthesis process, the carboxyl can be removed through trifluoroacetic acid subsequently, and the risk that an indole ring of tryptophan is reduced due to hydrogenation can be successfully avoided. According to the present invention, by using the solid phase synthesis method, the fragment can be rapidly and efficiently obtained, the racemization problem during the condensation process can be effectively avoided, the urea is formed on the solid phase, the operation is simple and convenient, the hydrogen and the diphosgene are not used during the preparation process, the production is safe, the obtained product has characteristics of high yield and high purity, and the preparation steps are less.

The invention belongs to the technical field of medicines, and particularly relates to an artificial toad venom composition and application thereof, and the core component of the composition comprises one or more of toad cardiotonic steroids, toad tryptamine or toad polypeptides. The invention designs a key raw material, a formula and a preparation method of artificial venenum bufonis, and particularly develops a method for effectively obtaining toad cardiotonic steroid components from plants. Pharmacodynamic evaluation proves that the artificial venenum bufonis composition prepared by the method has the effect equivalent to or close to that of natural venenum bufonis, and has the value for preparing natural venenum bufonis substitutes. According to the invention, sustainable resource guarantee is provided for Chinese patent medicines containing venenum bufonis, and support is provided for wild toad resources and ecological protection in China. The invention also comprises the design and development of a new medicine taking the artificial venenum bufonis composition or the raw materials thereof as components.

The present application provides an extract based on seabuckthorn seed meal and having the effects of improving sleep and memory. The present application also provides the use and detection method of the extract.

The disclosure relates to (2-{4-[(methoxycarbonyl)oxy]-1H-indol-3-yl}ethyl)bis(propan-2-yl)azanium chloride (4-methylcarbonato-N,N-diisopropyltryptramine chloride or 4-methylcarbonato-DiPT chloride), crystalline 4-methylcarbonato-DiPT chloride, [2-(1H-indol-3-yl)ethyl](propan-2-yl)amine (N-isopropyltryptamine or NiPT), crystalline NiPT, N-[2-(1H-indol-3-yl)ethyl]propan-2-amine hydrobromide (N-isopropyltryptamine hydrobromide or NiPT hydrobromide), crystalline NiPT hydrobromide, N-[2-(1H-indol-3-yl)ethyl]cyclohexanamine (N-cyclohexyltryptamine), crystalline N-cyclohexyltryptamine, 2-(1H-in-dol-3-yl)ethanamine (tryptamine), crystalline tryptamine, N-[2-(1H-indol-3-yl)ethyl]cyclohexanamine hydrobromide (N-cyclohexyltryptamine hydrobromide), crystalline N-cyclohexyltryptamine hydrobromide, and specific crystalline forms thereof, including crystalline form 1 of 4-methylcarbonrato-DiPT chloride, crystalline form 1 of NiPT, crystalline form 1 of NiPT hydrobromide, crystalline form 1 of N-cyclohexyltryptamine, crystalline form 1 of tryptamine, and crystalline form 1 of N-cyclohexyltryptamine hydrobromide, to compositions containing the same, and to methods of treatment using them.

The present invention relates to a recombinant Saccharomyces cerevisiae cell comprising the nucleotide sequences that encode for a L-tryptophan decarboxylase enzyme, a tryptamine 5-hydroxylase enzyme and a modified ARO4 K229L enzyme. Said cell is capable of producing serotonin from a simple carbon source, such as glucose, and from ammonia as a nitrogen source.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.

Provided herein are tetracyclic heterocyclic compounds useful in methods of treating a disease or for increasing neural plasticity. These compounds can also be used to increase dendritic spine density.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.

The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The disclosure further provides a method of stimulating neurogenesis or neurite growth resulting in an increase in neuronal length.

5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient suffering from a sleep disorder wherein the 5-MeO-DMT, or a pharmaceutically acceptable salt thereof, is administered via the intravenous, intramuscular or subcutaneous route.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a psychiatric or nervous system disorder in mothers of children aged 18 months or less.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.

Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.